KNSA KPL-387: Monthly IL-1 Shot Targets $1B Arcalyst

Recurrent pericarditis is not a disease most investors have heard of. It affects roughly 40,000 patients in the US, causes repeat episodes of chest pain and inflammation around the heart, and has exactly one FDA-approved biologic: Kiniksa’s own Arcalyst (rilonacept). That drug generated $243.6 million in Q2 2026 revenue, up 55% year over year, with full-year guidance raised to $980 to $995 million. Kiniksa trades at $78.20 with a $6.1 billion market cap, roughly 7.3x that 2026 revenue guide.

Now Kiniksa is trying to replace its own product. KPL-387 is a long-acting anti-IL-1alpha monoclonal antibody designed for monthly subcutaneous dosing, compared to Arcalyst’s weekly injection schedule. The Phase 2 dose-finding data from the KPL-387-C211 trial (NCT07010159) is expected in the second half of 2026. This is a self-cannibalization story with a better drug, and the market is paying 7x sales for the privilege of watching it play out.

The Arcalyst Franchise Kiniksa Is Building On

Arcalyst is no small asset. The drug earned FDA approval for recurrent pericarditis based on the RHAPSODY Phase 3 trial, a randomized-withdrawal design published in the New England Journal of Medicine. The results were striking: rilonacept produced a 96% reduction in risk of recurrent pericarditis events (hazard ratio 0.04, p<0.0001). Among patients who achieved clinical response during the run-in period, 81% maintained that response at Week 16 on rilonacept versus 20% on placebo (p=0.0002). The median time to recurrence on placebo was 8.6 weeks. On rilonacept, it could not be estimated because too few patients recurred.

That efficacy translated into a commercial trajectory few rare disease drugs achieve. Arcalyst revenue went from $180.9 million in Q3 2025 to $243.6 million in Q2 2026, with Kiniksa raising guidance twice. The 2026 midpoint of $987.5 million represents better than 50% growth over 2025’s total. Kiniksa splits profits with Regeneron, which originally discovered rilonacept, but the economics still flow through to KNSA’s bottom line. Q2 2026 net income was $25.4 million, up from $17.8 million a year earlier.

What KPL-387 Brings to the Table

KPL-387 is a monoclonal antibody that selectively targets IL-1alpha, one of two interleukin-1 signaling molecules that drive pericarditis inflammation. Arcalyst (rilonacept) is a soluble fusion protein that traps both IL-1alpha and IL-1beta. The selective approach may offer a different safety profile, though the clinical significance of blocking one IL-1 pathway versus both remains an open question.

The real selling point is dosing. Arcalyst requires weekly subcutaneous injections. KPL-387 is designed for once-monthly subcutaneous administration in a liquid formulation. For a chronic disease where patients face years or decades of therapy, cutting injection frequency by 75% is a meaningful quality-of-life improvement. It could also support premium pricing. Patients and physicians prefer less frequent dosing, and payers generally accept a premium for compliance advantages in rare diseases with limited alternatives.

The Phase 2/3 trial (KPL-387-C211, NCT07010159) is enrolling patients with recurrent pericarditis despite standard therapy. The Phase 2 dose-finding portion evaluates four regimens: 300 mg biweekly, 300 mg monthly, 100 mg biweekly, and 100 mg monthly. The primary outcome for Phase 2 is time to treatment response by Week 24, with secondary measures including CRP normalization, pain response on the numerical rating scale, and proportion of days with no or minimal pain. The Phase 3 portion will use the annualized rate of pericarditis recurrence as its primary endpoint, echoing the RHAPSODY design that won Arcalyst its approval.

The Self-Cannibalization Math

Here is where the story gets interesting for investors. If KPL-387 succeeds, it does not add a new market. It replaces an existing one. Arcalyst is on track for nearly $1 billion in 2026 revenue. KPL-387 would cannibalize that revenue stream, at a higher price point but with the same 40,000-patient addressable market.

The net revenue impact depends on three variables: how much of the Arcalyst patient base switches to KPL-387, whether the monthly formulation commands a pricing premium, and whether better compliance expands the treated population. Even in the best case, the incremental revenue from switching existing patients is a fraction of the gross. This is not a growth story. It is a franchise defense story. For more on this framework, see our orphan drug pricing explainer.

The comparison to Gilead’s HIV franchise is instructive. When a company files a new drug that competes with its own $1B+ drug, the net revenue impact is near zero because most prescriptions are switches, not new patients. Kiniksa is in a similar position, albeit at a smaller scale. The difference is that KPL-387 is still in Phase 2, not at a PDUFA date. The risk that the data does not support approval is real, and the stock at 7x sales is pricing in a successful transition.

Competitive Context

The IL-1 inhibitor space is niche but not empty. Novartis markets Ilaris (canakinumab), an anti-IL-1beta monoclonal antibody approved for periodic fever syndromes but not for pericarditis. It has been used off-label in recurrent pericarditis patients who fail colchicine and corticosteroids, and Novartis has explored Phase 2 development in the indication. Swedish Orphan Biovitrum’s Kineret (anakinra), a recombinant IL-1 receptor antagonist, is also used off-label. Neither has the FDA approval for recurrent pericarditis that Arcalyst holds.

Kiniksa’s first-mover advantage in the approved indication is significant. Physicians are already prescribing Arcalyst, the reimbursement pathways are established, and the clinical data from RHAPSODY is in the label. KPL-387 would enter as a line extension within the same company, not a competitive entrant. For broader context on the rare disease PDUFA calendar, see our rare disease catalysts roundup.

Valuation: Pricing Perfection at 7x Sales

At $78.20 and a $6.1 billion market cap, KNSA trades at approximately 7.3x its 2026 revenue guidance midpoint of $987.5 million. That is a premium multiple for a single-product rare disease company. For comparison, rare disease companies with approved drugs typically trade at 4 to 8x forward revenue depending on growth rate, pipeline depth, and patent runway. Kiniksa’s 55% revenue growth justifies a multiple at the high end of that range, but not much higher.

The valuation embeds two assumptions: that Arcalyst revenue continues to compound at 40%+ for the foreseeable future, and that KPL-387 successfully extends the IL-1 franchise. If the Phase 2 data disappoints, the stock loses the pipeline premium and reverts toward a pure-play Arcalyst valuation. At 5x revenue, that would imply a market cap of roughly $4.9 billion, or about $63 per share. That is a 19% downside from current levels on a Phase 2 miss.

On the upside, strong Phase 2 data that supports monthly dosing with competitive efficacy would validate the self-cannibalization thesis. The stock could re-rate toward 8 to 9x revenue as the market prices in a successful KPL-387 launch, implying $78 to $88 per share at the current revenue base. The upside is modest because the revenue base does not change. KPL-387 does not open a new market. It defends the existing one with a better formulation. For more on biotech valuation methodologies, see our valuation framework guide.

Risks

The primary risk is Phase 2 failure. The trial is open-label in its dose-finding portion, meaning there is no placebo control for the efficacy signal. The primary endpoint, time to treatment response, is a softer measure than the recurrence rate that won Arcalyst its approval. A weak signal here delays the Phase 3 start and pushes the KPL-387 timeline into 2028 or beyond.

The second risk is safety. Chronic IL-1 inhibition carries infection risk, and a monoclonal antibody delivered monthly means sustained exposure between doses. If serious infections emerge at a higher rate than Arcalyst’s established safety profile, the dosing advantage evaporates. The RHAPSODY trial showed that Arcalyst was well tolerated with adverse events consistent with its label, but KPL-387 is a different molecule with a different pharmacokinetic profile.

The third risk is competitive. If Novartis secures pericarditis approval for Ilaris, Kiniksa loses its monopoly. Canakinumab is already approved for multiple autoinflammatory conditions and has an established safety record. A head-to-head market share battle would compress pricing and slow growth, though this is a 2027 or later risk at earliest. For investors tracking the broader neuroscience and inflammation catalyst calendar, see our neuroscience catalysts guide.

Verdict

KNSA is not a buy here. The stock at 7.3x revenue is pricing in a successful Phase 2 readout and continued Arcalyst hypergrowth. The Phase 2 data is the near-term binary, and the upside is capped by the self-cannibalization dynamic: KPL-387 does not create a new market, it defends the existing one. A Phase 2 miss sends the stock to the low $60s. A Phase 2 hit keeps the stock where it is or pushes it marginally higher.

The trade to consider is a post-data position. If Phase 2 data is strong and the stock pulls back on profit-taking, the entry point becomes more attractive. Kiniksa is a real company with a real franchise, but the risk-reward at $78 is asymmetric to the downside. Arcalyst alone does not justify 7x sales without pipeline validation, and the pipeline validation is weeks to months away. For a framework on how to approach trial readouts as investment catalysts, see our phase 3 readout trading guide.

Hold for existing shareholders. Watch the data. Buy the reaction, not the anticipation.